[Integrated pharmaceutical care programme in patients with chronic diseases]

Chronic diseases like heart failure and COPD require ongoing medical attention. Previous studies have shown that medication-related problems are common in these populations. However, the impact of coordinated pharmaceutical interventions remains unclear. Existing research suggests that medication errors can lead to avoidable complications. No prior work had resolved whether integrated care models can reduce these issues. This gap motivated the need for a structured care program. Prior research has shown that pharmacists can identify and resolve medication issues. That uncertainty drove the design of a multi-centre trial. No prior work had resolved whether such programs improve health outcomes or reduce costs.

The aim of this study was to evaluate the effectiveness of an integrated pharmaceutical care programme in patients with chronic diseases. The specific problem addressed was the lack of evidence on whether such programs improve clinical outcomes or reduce health costs. The motivation came from the high prevalence of medication-related problems in chronic disease management. The study sought to determine if coordinated care could reduce avoidable medication issues. It also aimed to assess the impact on patient quality of life and healthcare utilization. The study focused on patients with heart failure and COPD. The researchers proposed that pharmacist involvement could improve medication safety. This approach could inform future healthcare delivery models.

The study used a parallel, open, multi-centre clinical trial design. Participants were patients with heart failure and/or COPD in eight health areas in Cataluña. The intervention group received monitoring by hospital pharmacists, primary care physicians, and community pharmacists. The control group received standard care without additional monitoring. All patients were followed for 12 months. Quality of life assessments were conducted at baseline and end of follow-up. Medication-related problems were identified and categorized. The study included 238 patients, with 2.9% lost to follow-up. Data collection involved electronic and manual tracking of health outcomes.

The study found no significant differences in readmissions, doctor visits, or emergency service use between groups. However, 50 medication-related problems were detected in 37 patients. There was a statistically significant difference in MRPs between treatment and control groups for heart failure patients. The difference was nearly significant for COPD patients. Of the MRPs, 36% were moderate to severe in nature. The majority of MRPs were avoidable, with 94% deemed preventable. Pharmacists resolved 90% of these issues. No changes in quality of life or health costs were observed over the study period.

The authors suggest that integrated pharmaceutical care programs may improve the quality of patient care. They propose that such programs could help identify and resolve medication-related problems. The researchers note that electronic registries are necessary to enhance communication across healthcare sectors. They suggest that without such systems, the full potential of these programs may not be realized. The study did not find significant improvements in health outcomes or costs. The authors suggest that further research is needed to confirm these findings. They propose that pharmacist involvement is valuable in managing chronic disease medications. The authors conclude that structured care models may support safer medication use.